Bellevue Asset Management (Switzerland)’s Juno Therapeutics, Inc. JUNO Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$1.63M	Buy	37,000 +4,000	+12%	+$198K	0.25%	92
2015 Q3	$1.34M	Sell	33,000 -15,000	-31%	-$658K	0.22%	98
2015 Q2	$2.56M	Buy	+48,000	New	+$2.55M	0.36%	76

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s JUNO Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) increased its Juno Therapeutics, Inc. (JUNO) stake by 12% in Q4 2015, buying an estimated $198K and bringing the position to 37,000 shares worth $1.63M. The position accounts for 0.25% of the portfolio, ranked #92.

Bellevue Asset Management (Switzerland) first reported a position in JUNO in Q2 2015 and has held it in 3 quarters since. The position peaked at $2.56M in Q2 2015. 160 funds tracked by Wall St. Rank hold JUNO as of Q4 2015.

Bellevue Asset Management (Switzerland) held 37,000 shares of Juno Therapeutics, Inc. worth $1.63M as of Q4 2015.
Bellevue Asset Management (Switzerland) bought 4,000 Juno Therapeutics, Inc. shares in Q4 2015, an estimated $198K.
Juno Therapeutics, Inc. made up 0.25% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #92 holding.
Bellevue Asset Management (Switzerland) first reported a position in Juno Therapeutics, Inc. in Q2 2015 and has held it in 3 quarters since.
Bellevue Asset Management (Switzerland)'s Juno Therapeutics, Inc. position peaked at $2.56M in Q2 2015.
160 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.